IP Library Granted Patent US 7,183,062
Granted Patent B2
US 7,183,062 · App. 10/747,994 · Granted Feb 27, 2007

Prostaglandin receptor protein and methods of use thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,183,062
App. No.
10/747,994
Granted
Feb 27, 2007
Kind
B2
Abstract

Described herein is a novel member of the prostanoid receptor family, a guinea pig prostaglandin D2 receptor. Described are the receptor, the nucleic acid that encodes it, and various uses for both.

Claims (15)

1. A method for identifying an agonist of SEQ ID NO:2, the method comprising the steps of:

a) contacting a test compound with a cell expressing SEQ lID NO:2;

b) detecting a signal mediated by SEQ ID NO:2 in the presence of said test compound; and

c) determining whether in the presence of said test compound the signal of SEQ ID NO:2 is increased relative to the signal of SEQ ID NO:2 in the absence of said test compound;

wherein the increased signal identifies the test compound as an agonist.

2. A method for identifying an inverse agonist of SEQ ID NO:2, the method comprising the steps of:

a) contacting a test compound with a cell expressing SEQ ID NO:2;

b) detecting a signal mediated by SEQ ID NO:2 in the presence of said test compound; and

c) determining whether in the presence of said test compound the signal of SEQ ID NO:2 is decreased relative to the signal of SEQ ID NO:2 in the absence of said test compound;

wherein the decreased signal identifies the test compound as an inverse agonist.

3. A method for identifying an antagonist of SEQ ID NO:2, the method comprising the steps of:

a) contacting a test compound with a cell expressing SEQ ID NO:2;

b) detecting a signal mediated by SEQ ID NO:2 in step a) in both the presence and absence of an agonist of SEQ lID NO:2; and

c) determining whether in the presence of said agonist the signal of SEQ ID NO:2 in the presence of said test compound is decreased relative to the signal of SEQ ID NO:2 in the absence of said test compound;

wherein the decreased signal identifies the test compound as an antagonist.

Assignments (3)
MERGER Recorded Jan 19, 2015
From: AVENTIS PHARMACEUTICALS INC.
To: AVENTISUB LLC
Reel/Frame 034781/0334 →
CERTIFICATE OF CONVERSION Recorded Dec 9, 2014
From: AVENTISUB INC.
To: AVENTISUB LLC
Reel/Frame 034566/0976 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2004
From: PARKAR, ASHFAQ; AUGUST, PAUL; KUNTZWEILER, THERESA; ARDATI, MOHAMAD ALI; BASKARAN, NAMADEV
To: AVENTIS PHARMACEUTICALS INC.
Reel/Frame 014733/0774 →